resiquimod

chemical compound

Uses your system voice; voice and rate in settings.

Q426054Snapshot

≈ 2 min read

Names in other languages

  • DeutschResiquimod
  • Englishresiquimod
  • FrançaisResiquimod
  • NederlandsResiquimod
  • shRezikuimod
  • СрпскиRezikuimod
  • СрпскиРезикуимод
  • СрпскиRezikuimod

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel in the treatment of skin lesions such as those caused by the herpes simplex virus and cutaneous T cell lymphoma, and as an adjuvant to increase the effectiveness of vaccines.

In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8, and an upregulator of the opioid growth factor receptor.

On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1332215366 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.